KL-6在间质性肺疾病诊治中的研究进展

Advances in the research on application of KL-6 in the diagnosis and treatment of interstitial lung disease

间质性肺疾病(ILD)是一组主要累及肺间质和肺泡腔,导致肺泡-毛细血管功能单位丧失的弥漫性肺疾病,同时也是类风湿关节炎、皮肌炎、系统性硬化症患者的常见并发症和影响预后的重要因素。寻找能够早期诊断ILD并评价其病情活动度的生物标记物一直是研究的热点。表达于Ⅱ型肺泡上皮细胞的KL-6目前被认为是诊断ILD最具前景的生物标记物。本文对近年来有关KL-6在ILD诊治中的研究进展做一综述。

Interstitial lung disease represents a group of diffuse pulmonary diseases that mainly affects pulmonary mesenchyme and alveolar spaces, resulting in loss of alveolar-capillary functions. It is also a common complication or an important factor that influences the prognosis of rheumatoid arthritis, dermatomyositis, systemic sclerosis. Searching for the biomarkers for the early diagnosis of the disease and/or indicative of the activity of the condition has been a subject of active investigations. KL-6, expressed on type II pneumocytes, is seen as the most promising biomarker for the diagnosis of the disease. This review summarizes the recent researches about the use of KL-6 in the diagnosis and treatment of interstitial lung disease.